Shanxi Xinyu Pharmaceutical Co. Ltd.

Main objective: To investigate the bioequivalence of the two preparations in healthy volunteers by comparing the absorption rate and extent of diclofenac diethylamine emulsion provided by Shanxi Zechen Pharmaceutical Technology Co., Ltd. with that of diclofenac diethylamine emulsion (reference preparation) certified by Haleon Schweiz AG, using diclofenac diethylamine emulsion provided by Shanxi Zechen Pharmaceutical Technology Co., Ltd. as the test preparation according to the relevant regulations of bioequivalence studies.

Main study objectives To study the pharmacokinetics of the test preparation Dotinol tablets (specification: 2 mg, licensed by Shanxi Zechen Pharmaceutical Technology Co., Ltd.) and the reference preparation Dotinol tablets (trade name: URECE®, specification: 2 mg, licensed by Fuji Pharmaceutical Co., Ltd.) in healthy adult subjects after single oral administration in fasting and postprandial states, and to evaluate the bioequivalence of the two preparations when taken orally in fasting and postprandial states. Secondary study objectives To study the safety of the test preparation Dotinol tablets and the reference preparation Dotinol tablets in healthy adult subjects.

Primary objective: To study the pharmacokinetics of the test formulation upadacitinib extended-release tablets (specification: 15 mg, licensed by Shanxi Zechen Pharmaceutical Technology Co., Ltd.) and the reference formulation upadacitinib extended-release tablets (trade name: RINVOQ®/Rinvoq®, specification: 15 mg, licensed by AbbVie Deutschland GmbH & Co. KG) in healthy adult subjects after a single oral dose in fasting and fed states, and to evaluate the bioequivalence of the two oral formulations in fasting and fed states.